A Phase 3 interventional study of Bisoprolol and Ivabradine in Cardiovascular Diseases, sponsored by Ain Shams University. Completed at 1 site in Egypt. Open to male participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2018-04-02.
Sponsored by Ain Shams University · Phase 3, Interventional, and Other
The purpose of the study was to investigate the potential interaction between ivabradine and bisoprolol in healthy subjects.
The aim of this study is to undergo a pharmacokinetic study to investigate the incidence of potential pharmacokinetic interaction between Ivabradine and Bisoprolol through the Assessment of the drug-drug interactions of Ivabradine and Bisoprolol by determination of pharmacokinetic parameters of both drugs administered alone and in combination. The pharmacokinetic parameters will include; The maximum plasma concentration (Cmax),the time to reach the peak concentration (tmax), area under the concentration-time curve (AUC0-t) and (AUC0-∞) during the treatment periods, the absorption and elimination rate constants (ka and kel), the half-life and mean residence time (MRT).
Study design A comparative randomized open-label three-period crossover study of ivabradine/ bisoprolol in male healthy human volunteers
Methodology
Eighteen healthy volunteer will be recruited in the study and will be divided into three groups each consisting of six volunteers as follows:
Period I:
Period II:
Period III:
All drug administration will be followed by 240 ml of water after at least 10 h fasting prior to administration. The three treatment periods will be separated by a one week washout period. Standardized meals will be served at 2, 5, and 10 h after drug dosing. All subjects should abstain from the consumption of fruit juices during the study period.
Subject Selection Criteria Eighteen adult male volunteers will be enrolled. Subjects should understand the procedures and are willing to participate and give their final written consent prior to the commencement of the study procedures.
Subjects should be healthy adult volunteers with age between (18-45 years) with normal body weight. Subjects should understand the procedures and are willing to participate and gave their final written consent prior to the commencement of the study procedures. The volunteers will be asked to provide a complete medical history, and complete a physical examination, laboratory tests [hematology, clinical chemistry, urinalysis, serology (including hepatitis B surface antigen, anti-hepatitis C virus and antihuman immunodeficiency virus antibody).
Exclusion Criteria:
six healthy volunteers will administer Ivabradin tablet only once single 10 mg oral dose
Drug: Ivabradine
six healthy volunteers will administer bisoprolol tablet only once single oral dose of 5mg
Drug: Bisoprolol
six healthy volunteers will administer only once a combination of a single dose of ivabradine 10 mg and bisoprolol 5 mg
Drug: combination of Ivabradine and bisoprolol
bisoprolo 5 mg tablets
Also known as: Concor
Ivabradine 10 mg tablet
Also known as: Procorloan
combination of 10 mg ivabradine and 5 mg bisoprolol
Also known as: concor plus procorolan
Pharmacokinetic parameters
AUC0→∞
Time frame: 48 hours
Pharmacokinetic parameters
AUC0→t
Time frame: 48 hours
Bioavailability parameters
Cmax
Time frame: 48 hours
Bioavailability parameters
t max
Time frame: 48 hours
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ain Shams University